MARISA ADLESICH: Open Payments
NPI 1679047708 · TIGARD, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$621 in 27 payments from 21 companies in 2025. Trend: 2023 $251 · 2024 $621 · 2025 $621
Food & beverage: $621
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 5 | $105 |
| GENZYME CORPORATION | 2 | $46 |
| Genentech USA, Inc. | 2 | $40 |
| Astellas Pharma US Inc | 1 | $34 |
| TerSera Therapeutics LLC | 1 | $32 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $32 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Eisai Inc. | 1 | $27 |
| Genmab U.S., Inc. | 1 | $26 |
| GlaxoSmithKline, LLC. | 1 | $26 |
Products named: KISQALI, PADCEV, Zoladex, Nubeqa, ORGOVYX, Lenvima, SARCLISA, Epkinly.
Industry payments across OR — which companies pay providers there.
